Trial Profile
Penetration of moxifloxacin in bronchial secretions in hospitalised patients with acute exacerbation of COPD
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 31 Aug 2015
Price :
$35
*
At a glance
- Drugs Moxifloxacin (Primary)
- Indications Chronic obstructive pulmonary disease; Respiratory tract infections
- Focus Pharmacokinetics
- 31 Aug 2015 New trial record